StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Research analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other research firms have also issued reports on CLLS. Oppenheimer reiterated an “outperform” rating and set a $11.00 target price on shares of Cellectis in a report on Tuesday, August 8th. JMP Securities reiterated a “market outperform” rating and set a $6.00 target price on shares of Cellectis in a report on Wednesday, November 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.75.

Cellectis Price Performance

CLLS stock opened at $2.51 on Monday. The firm has a 50 day moving average price of $1.67 and a 200-day moving average price of $1.87. Cellectis has a 52-week low of $0.96 and a 52-week high of $4.04. The firm has a market capitalization of $139.52 million, a price-to-earnings ratio of -1.50 and a beta of 2.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.69 and a current ratio of 2.20.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new position in Cellectis in the 3rd quarter worth approximately $30,000. Virtu Financial LLC purchased a new position in Cellectis in the 2nd quarter worth approximately $46,000. Balyasny Asset Management LLC purchased a new position in Cellectis in the 3rd quarter worth approximately $42,000. Envestnet Asset Management Inc. raised its holdings in Cellectis by 19.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 20,501 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,305 shares during the last quarter. Finally, OLD Mission Capital LLC raised its holdings in Cellectis by 90.0% in the 1st quarter. OLD Mission Capital LLC now owns 22,329 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 10,577 shares during the last quarter. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.